Cellceutix to Request Meeting With FDA for Phase 2 Ovarian

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines the Pharmacokinetic Profile of Kevetrin

BEVERLY, MA --(Marketwired - October 26, 2015) - Cellceutix Corporation ( OTC : CTIX ) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders that the Kevetrin trial for advanced solid tumors is providing important data on the pharmacokinetic (PK) profiles of the drug when administered in single doses over a wide range of concentrations and over differing durations of the intravenous infusion. This dose-ranging trial is near completion. We have collected enough data for planning Phase 2 trials. This data is being used to design the Kevetrin dosing regimen for the planned studies in patients with advanced ovarian carcinoma. The FDA meeting request is planned to be submitted this week.

To date, PK profiles found that the plasma half-life of Kevetrin is relatively short, supporting the projected administration of multiple infusions each week in the next study. The half-lives after the first dose and after the sixth dose do not differ appreciably.

Longer durations of Kevetrin infusion have shown prolonged exposure to the drug. Prolonged exposure and high area-under-the-curve (AUC) may be desirable in therapy of solid tumors especially with Kevetrin since activation of cell death signaling requires multiple gene synthesis and the phase or phases of the tumor cell cycle most susceptible to the effect(s) of Kevetrin is not known.

The Company has now gathered very valuable information from the Kevetrin Phase 1 study for planning mid-stage trials of Kevetrin. The PK data are reinforcing the Company's belief that with its short half-life, Kevetrin may provide an even greater therapeutic benefit with multiple weekly treatments. Since Kevetrin acts through transcription factor p53 and regulates many pro-apoptotic genes, the sustained exposure of Kevetrin is required to activate the apoptotic pathways in tumors. Cellceutix's goal is for the patient to have prolonged exposure to Kevetrin by dosing multiple times so that the tumor with different stages of mutations get ample time to activate the cell death signaling. As we have stated, we are now turning our attention to advance evaluation of Kevetrin in a Phase 2 study in patients with ovarian carcinoma for which Kevetrin was granted an orphan drug designation earlier this year. To help patients and develop the best medicines is why we the employees, with support from our shareholders, work so tirelessly at Cellceutix. We acknowledge the support and assistance of the Phase 1 trial's investigators at Dana Farber and Beth Israel Deaconess, including the pharmacokinetic laboratory, for lending their expertise in the development of our novel compound.

Alerts:

Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.CRfqSmmY.dpbs

Cellceutix clinical trials on Clinicaltrials.gov:

https://clinicaltrials.gov/ct2/results?term=c...rch=Search

About Cellceutix:

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com .

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 204

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 253

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

CorMedix Achieves 52-Week High Amidst Business Expansion Strategies

Updated Category News Views 122

CorMedix Stock Reaches New Heights CorMedix Inc. has recently celebrated a milestone by reaching a new 52-week high, with shares hitting $10.15. This significant achievement comes as part of a broader trend of notable expansion and investor confidence in the pharmaceutical and medical device sector. Over the past year, CorMedix's stock has increased by an impressive...

Continue Reading
Norway's Wealth Fund Shifts Ethics Standards Amid Gaza Conflict

Updated Category News Views 148

Norway's Wealth Fund Takes a Stand on Ethical Investments Norway's $1.7 trillion wealth fund is currently navigating a challenging ethical landscape as it considers pulling investments from companies associated with operations in the occupied Palestinian territories. The fund's Council on Ethics has adopted a stricter interpretation of its ethical standards, which could...

Continue Reading
Bonduelle's Monthly Share and Voting Rights Update

Updated Category News Views 120

Overview of Bonduelle's Monthly Share and Voting Rights Update Bonduelle, a prominent player in the food industry, is well-known for its commitment to providing high-quality vegetable products. Headquartered in an innovative facility, their corporate structure includes a significant capital invested which showcases their strong market presence. Latest Information on...

Continue Reading
Innovative Partnership Launches Unique Aging and Cancer Research Institute

Updated Category News Views 193

Innovative Partnership in Cancer Research The Mark Foundation for Cancer Research (MFCR) and the Samuel Waxman Cancer Research Foundation (SWCRF) have entered a groundbreaking collaboration to create the Samuel Waxman Institute for Aging & Cancer. This institute will serve as the first dedicated global center exploring how aging impacts cancer risk throughout a person's...

Continue Reading
Market Overview: Nasdaq Surges as Stocks Show Mixed Trends

Updated Category News Views 201

Market Overview: Nasdaq Shows Strength The U.S. stock markets experienced a mixed performance recently, with the Nasdaq Composite recording a notable gain of over 50 points. This uptick brings attention to sector volatility and specific stock behaviors that investors should closely monitor. Daily Market Trends After the markets opened, the Dow Jones Industrial Average saw...

Continue Reading